Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial - Publication - Bridge of Knowledge

Your account

login

Search

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Abstract

Citations

  • 6 4

    CrossRef

  • 0

    Web of Science

  • 6 8

    Scopus

Authors (17)

  • Photo of Won Kim

    Won Kim

  • Photo of Christian Buske

    Christian Buske

  • Photo of Michinori Ogura

    Michinori Ogura

  • Photo of MD, PhD, Prof Wojciech Jurczak

    Wojciech Jurczak MD, PhD, Prof

  • Photo of Juan-Manuel Sancho

    Juan-Manuel Sancho

  • Photo of Edvard Zhavrid

    Edvard Zhavrid

  • Photo of Jin Kim

    Jin Kim

  • Photo of José-Ángel Hernández-Rivas

    José-Ángel Hernández-Rivas

  • Photo of Aliaksandr Prokharau

    Aliaksandr Prokharau

  • Photo of Mariana Vasilica

    Mariana Vasilica

  • Photo of Rajinish Nagarkar

    Rajinish Nagarkar

  • Photo of Dzhelil Osmanov

    Dzhelil Osmanov

  • Photo of Larry Kwak

    Larry Kwak

  • Photo of Sang Lee

    Sang Lee

  • Photo of Sung Lee

    Sung Lee

  • Photo of Yun Bae

    Yun Bae

  • Photo of Bertrand Coiffier

    Bertrand Coiffier

Cite as

Full text

full text is not available in portal

Details

Category:
Magazine publication
Type:
Magazine publication
Published in:
Lancet Haematology no. 4, edition 8, pages e362 - e373,
ISSN: 2352-3026
ISSN:
2352-3026
Publication year:
2017
DOI:
Digital Object Identifier (open in new tab) 10.1016/s2352-3026(17)30120-5
Verified by:
No verification

seen 39 times

Meta Tags